SUPPLEMENTAL MATERIAL

Table S1. Summary level data from trials used as inputs for Monte-Carlo simulations.

	EMPAREG-OUTCOME trial			PARADIGM trial	
	Empagliflozin	Placebo		Sacubitril-Valsartan	Enalapril
Sample size	**4,687**	**2,333**		**4,187**	**4,212**
Person-years follow up	13,866	6,783		9,491	9,407
All-cause deaths	269	194		711	835
CV deaths	172	137		558	693
Incidence rate/100 py all-cause deaths	1.94	2.86		7.49	8.88
Incidence rate/100 py CV deaths	1.24	2.02		5.88	7.37

Table S2. Input parameter ranges used in the Monte Carlo simulations.

Outcome assessment appraoch	False positive rate	Sensitivity		
		Non differential misclassification	Differential misclassification	
			Treatment	Reference
1. All-place all-cause mortality: Master Beneficiary Summary File or hospitalization claims with discharge status of death	0	0.99207-0.99997	-	-
2. In-hospital all cause mortality: Hospitalization claims with discharge status of death	0	0.2771-0.3371	0.30-0.35	0.25-0.30
3. All-place cardiovascular mortality:	0.2878-0.3616	0.5201-0.5383	0.55-0.60	0.50-0.55
4. In-hospital cardiovascular mortality:	0.1375-0.1901	0.2027-0.2234	0.20-0.25	0.15-0.20